文献速递抗菌药物管理药物相互作用肝肾功能剂量调整

药师主导的抗逆转录病毒药物管理在社区医院对ART相关用药错误的影响

Assessing the impact of pharmacist-led antiretroviral stewardship In community hospitals on antiretroviral-related medication errors.
PubMed 文献 · Am J Health Syst Pharm · 2026-01-01

本研究为多中心回顾性病历审查,纳入6家社区医院2024年5月至7月收治的153例接受抗逆转录病毒治疗(ART)的患者。药师干预组ART相关用药错误率为7.5%(5例),显著低于非干预组的23%(20例;P=0.009),支持在社区医院开展抗逆转录病毒药物管理以改善HIV住院患者用药安全。

要点

  • 药师干预组ART相关用药错误率7.5%,显著低于非干预组23%(P=0.009)。
  • 药师干预最常见类型为机会性感染预防(10例)。
  • 非干预组最常见错误为机会性感染预防不当或缺失(9例)。

核心结论

  • 在社区医院中,接受药师主导干预的患者ART相关用药错误率显著低于未干预患者,支持抗逆转录病毒药物管理在改善HIV住院患者用药安全中的作用。

研究设计与样本

  • 多中心回顾性病历审查,纳入6家社区医院2024年5月至7月收治的接受ART的患者。
  • 共247例接受ART,排除94例后最终纳入153例进行分析。

主要发现

  • 纳入患者平均年龄52岁,68%(104例)为男性。
  • CD4+ T细胞计数低于200 cells/mm³者占37%(57例),77%(118例)使用单一片剂方案。
  • 药师干预发生于67例(44%),其中机会性感染预防(10例)为最常见干预类型。
  • 药师干预组ART相关用药错误率为7.5%(5例),非干预组为23%(20例),差异有统计学意义(P=0.009)。
  • 药师干预组最常见错误为未处理的药物相互作用(3例);非干预组最常见错误为机会性感染预防不当或缺失(9例)。

关键数值与推荐

  • ART相关用药错误定义为:ART方案不完整、机会性感染预防不当或缺失、因肾功能导致的剂量调整错误、或未处理的药物相互作用。
  • 排除标准包括:因妊娠、新生儿、乙型肝炎、暴露前预防或暴露后预防接受ART,住院时间不足48小时,或入院48小时内死亡。

临床怎么用

  • 在社区医院对住院HIV患者开展药师主导的抗逆转录病毒药物管理,可降低ART相关用药错误率。
  • 药师应重点关注机会性感染预防、ART方案完整性、肾功能剂量调整及药物相互作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Antiretroviral stewardship programs have been recommended by several organizations, including the Infectious Diseases Society of America, to minimize medication errors that may adversely affect people living with human immunodeficiency virus (HIV). To date, the role of antiretroviral stewardship has largely been studied in tertiary or quaternary care medical centers with dedicated infectious diseases pharmacists, complex patient populations, and robust clinical laboratory services. Thus, limited data are available in lower-acuity community hospital settings. The purpose of this study was to evaluate the impact of pharmacist-led antiretroviral stewardship on antiretroviral therapy (ART)-related medication error rates in community hospital settings. METHODS: This was a multicenter retrospective chart review of patients receiving ART during admission to 6 community hospitals of a large health system between May and July 2024. ART-related medication errors were defined as incomplete ART regimens, inappropriate or absent opportunistic infection (OI) prophylaxis, incorrect dose adjustments due to renal function, or unaddressed drug-drug interactions (DDIs). Patients were excluded if they were receiving ART for pregnancy, neonates, hepatitis B, pre-exposure prophylaxis, or post-exposure prophylaxis, had a length of stay under 48 hours, or died within 48 hours of admission. RESULTS: Of 247 patients who received ART during the study period, 94 were excluded based on the predefined criteria, with 153 patients included in the final analysis. The mean age was 52 years, and 68% (n = 104) of patients were male. CD4+ T cell counts below 200 cells/mm³ were observed in 37% (n = 57) of patients, and 77% (n = 118) were on a single-pill regimen. Pharmacist interventions occurred in 67 patients (44%), with OI prophylaxis (n = 10) being the most frequent intervention. The rate of ART-related medication errors was significantly lower in the pharmacist intervention group (7.5%, n = 5) than in the nonintervention group (23%, n = 20; P = 0.009). In the pharmacist intervention group, unaddressed DDIs (n = 3) were the most common error, whereas in the nonintervention group errors most frequently included inappropriate or absent OI prophylaxis (n = 9), incomplete ART optimization (n = 6), unaddressed DDIs (n = 5), and incorrect renal dose adjustment (n = 2). CONCLUSION: In community hospital settings, ART-related medication error rates were significantly lower among patients who received pharmacist-led intervention, supporting the role of antiretroviral stewardship in improving medication safety in hospitalized persons with HIV.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Lee PK, Isajloska-Jasmak G, Aly S, et al. Assessing the impact of pharmacist-led antiretroviral stewardship In community hospitals on antiretroviral-related medication errors. Am J Health Syst Pharm. 2026. PMID: 41689280. doi:10.1093/ajhp/zxag049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。